Skip to main content

Zymeworks Inc(ZYME-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low5.30
Day High5.78
Open:5.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Business Wire - Mon Jun 27, 7:30AM CDT
Business Wire
Mon Jun 27, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as...
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Business Wire - Mon Jun 27, 7:30AM CDT
Business Wire
Mon Jun 27, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as...
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Business Wire - Fri Jun 10, 8:15AM CDT
Business Wire
Fri Jun 10, 8:15AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the “Board”) has adopted a limited-duration shareholder rights plan...

Latest Articles

Zymeworks receives US$773-million buyout proposal from private capital firm All Blue
Zymeworks stock slumps after struggling Canadian biotech sells US$100-million in highly dilutive share offering